此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MYT1L综合征:一种导致神经发育障碍的罕见小儿遗传综合征 (MYT1L)

2026年11月3日 更新者:University Hospital, Rouen

MYT1L综合征中语言和韵律障碍的表征,认知功能和行为问题

MYT1L syndrome is a rare genetic syndrome, recently described in 2011, with paediatric onset, responsible for a neurodevelopmental disorder combining psychomotor retardation, learning difficulties and/or intellectual development disorders, epilepsy, overweight and eating disorders. The Rouen genetics department is currently positioned as a clinical expert in this disease.

The study published in 2020 by our team (Coursimault J et al., Hum Genet. 2022, PMID: 34748075) has enabled us to describe 40 new individuals worldwide, to gain a better understanding of this disease, to specify the genotype-phenotype relationships and to describe new clinical signs. We were able to confirm the presence of a neurodevelopmental disorder in 100% of patients, which includes: language delay, impaired orality, global and facial hypotonia, prosodic features and behavioural problems. This will be the first study in the world to characterise the neuropsychological, language and prosodic profiles of MYT1L patients.

研究概览

详细说明

Although neuropsychological and speech therapy assessment is part of the routine work-up of any patient with a neurodevelopmental disorder, the heterogeneous use of assessment scales has not made it possible to obtain a precise characterisation of the neuropsychological and language profile of patients with MYT1L syndrome in retrospective studies. As a result, it is not possible to establish specific language and behavioural rehabilitation treatments. The aim of the study is to provide substantiated information on language (oral language, speech), prosody (reception and expression) and cognitive-behavioural aspects (global IQ, executive functions, sensory profile, attention, aggression, intolerance to frustration, anxiety). This project proposes to carry out a protocol used in routine care to assess language, prosody, cognitive functions and mood disorders, with the aim of identifying a specific language, prosody, cognitive and behavioural profile of patients with MYT1L syndrome, which could lead to better assessment in the future, screening for disorders and better targeting of rehabilitation in future patients, and to identify profiles suggestive of MYT1L syndrome in patients who have not had genetic confirmation (no variation identified or variation of uncertain significance).

研究类型

介入性

注册 (实际的)

45

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Rouen、法国、76031
        • University Hospital of Rouen

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

MYT1L Group Patients

  • Minimum age for inclusion: 6 years
  • Maximum age for inclusion: no upper age limit
  • Language: French
  • Consent of parents or legal guardian
  • Social security coverage required

Prosody Group Patients

  • Unaided visual or hearing impairment making assessments impossible
  • Non-French speaking patients
  • Patients with a dual molecular genetic diagnosis also causing a neurodevelopmental disorder
  • Acquired neurological disorder

Exclusion Criteria:

MYT1L Group patients

  • Unaided visual or hearing impairment making assessments impossible
  • Non-French speaking patients
  • Patients with a dual molecular genetic diagnosis also causing a neurodevelopmental disorder
  • Acquired neurological disorder

Prosody Group Patients

  • Patients with molecularly confirmed MYT1L syndrome.
  • Nonverbal patients

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MYT1L Arm
  • Neuropsychological assessment by the neuropsychologist (lasting 1h30)
  • Speech and language assessment (including language and prosody) by the speech therapist, lasting 1h30
有源比较器:Control Arm

Consisting of verbally communicative patients with another genetically determinded neurodevelopmental disorder that has been confirmed at the molecular level.

Evaluation de la prosodie par l'orthophoniste (45 minutes)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Speech-language profile
大体时间:At enrollment visit

Evaluation of the neuropsychological profile during an interview with the neuropsychologist allowing the administration of standardized tests completed with the patient and through questionnaires completed by the family

At enrollment visit

次要结果测量

结果测量
措施说明
大体时间
Speech-language profile
大体时间:At enrollment visit

Assessment of the language profile through standardized tests completed with the patient during the interview with the speech therapist and questionnaires completed by the family

At enrollment visit
Prosodic speech therapy profile (patients with MYT1L syndrome)
大体时间:At enrollment visit

Evaluation of the prosodic profile of patients with MYT1L syndrome by voice recordings

At enrollment visit
Prosodic speech therapy profile (patients with a molecular diagnosis other than MYT1L)
大体时间:At enrollment visit

Evaluation of the prosodic profile of patients with a molecular diagnosis other than MYT1L by voice recordings

At enrollment visit

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年2月4日

初级完成 (实际的)

2026年3月20日

研究完成 (实际的)

2026年3月20日

研究注册日期

首次提交

2025年5月28日

首先提交符合 QC 标准的

2025年5月28日

首次发布 (实际的)

2025年6月6日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2024/0255/HP
  • 2024-A02492-45 (其他标识符:ANSM)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data provided will be the property of the sponsor and will be used solely for its own research activities.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅